“Stage 2 diabetes” most commonly refers to a specific phase in the progression toward type 1 diabetes, defined by a joint statement from JDRF, the Endocrine Society, and the American Diabetes Association. In this stage, the immune system has already begun attacking the insulin-producing cells of the pancreas, and blood sugar levels are starting to creep above normal, but the person has no obvious symptoms yet. A separate framework also uses “stage 2” to describe prediabetes on the path to type 2 diabetes. Both systems describe a window where the disease is detectable but hasn’t fully arrived.
Stage 2 Type 1 Diabetes
Type 1 diabetes develops in three recognized stages. Stage 1 means the immune system has produced at least two types of autoantibodies that target the pancreas, but blood sugar is still normal. Stage 2 means those same autoantibodies are present and blood sugar control has started to slip. Stage 3 is full-blown type 1 diabetes with clear symptoms like excessive thirst, frequent urination, and weight loss.
Stage 2 is the critical middle ground. The person still feels fine and may have no idea anything is wrong. But lab tests reveal what’s called dysglycemia: blood sugar that isn’t quite normal anymore. This can show up as a fasting blood sugar at or above 100 mg/dL, a two-hour glucose reading at or above 140 mg/dL after a sugar drink test, or an A1C at or above 5.7%. These numbers fall in the “prediabetes” range on standard tests, but the underlying cause is the immune system destroying insulin-producing beta cells rather than the insulin resistance that drives type 2 diabetes.
People in stage 2 have a roughly 75% chance of progressing to stage 3 type 1 diabetes within four to five years, and a lifetime risk approaching 100%. A German study of children with stage 2 found that those with two or more abnormal blood sugar markers had a 68% chance of reaching stage 3 within just two years, while those with only a single abnormality had about a 30% two-year risk.
How Stage 2 Is Detected
Because stage 2 type 1 diabetes causes no symptoms, it’s only found through blood tests. The key requirement is the presence of at least two different islet autoantibodies. Four types are currently available for clinical testing: antibodies against insulin (IAA), an enzyme called GAD (GADA), a protein called IA-2 (also known as ICA512), and a zinc transporter on the surface of beta cells (ZnT8A). Having two or more of these is the immune signature that separates autoimmune-driven blood sugar changes from ordinary prediabetes.
Most people discover they’re in stage 2 because a close relative has type 1 diabetes and they enrolled in a screening program, or because a research study flagged their autoantibodies. General screening of the broader population isn’t standard practice yet, though awareness is growing. Once autoantibodies are confirmed, doctors use fasting glucose, an oral glucose tolerance test, or A1C to determine whether the person is still in stage 1 (normal blood sugar) or has crossed into stage 2 (abnormal blood sugar).
An FDA-Approved Treatment Exists
In 2022, the FDA approved the first drug that can delay the progression from stage 2 to stage 3 type 1 diabetes. It’s approved for adults and children aged 8 and older who have at least two positive autoantibodies and dysglycemia. The treatment is given as an intravenous infusion once daily for 14 consecutive days.
In a clinical trial of 76 people with stage 2, 45% of those who received the drug progressed to stage 3 over a median follow-up of about four years, compared to 72% of those who received a placebo. The drug delayed onset by roughly two years on average. It doesn’t prevent or cure type 1 diabetes, but buying time before a person becomes dependent on insulin injections is meaningful, particularly for children. The 2025 ADA Standards of Care now recommend discussing this option with eligible patients aged 8 and older.
Stage 2 in Type 2 Diabetes Frameworks
If you searched “stage 2 diabetes” thinking about type 2 diabetes, there is a separate staging system that applies. The American Association of Clinical Endocrinology published a four-stage framework for what they call dysglycemia-based chronic disease. In that model, stage 1 is insulin resistance with normal blood sugar, stage 2 is prediabetes, stage 3 is type 2 diabetes, and stage 4 is type 2 diabetes with complications like nerve damage, kidney disease, or vision problems.
Under this framework, stage 2 lines up with prediabetes: an A1C between 5.7% and 6.4%, fasting blood sugar between 100 and 125 mg/dL, or a two-hour glucose tolerance reading between 140 and 199 mg/dL. At this point, the pancreas still produces insulin, but the body’s cells don’t respond to it efficiently. Beta cell function is already declining. By the time someone receives a formal type 2 diabetes diagnosis, roughly half of their beta cell function has already been lost.
The practical takeaway for stage 2 in the type 2 framework is that prediabetes is reversible with lifestyle changes. Weight loss, regular physical activity, and dietary shifts can bring blood sugar back into the normal range and prevent or significantly delay progression to full diabetes.
Why the Distinction Matters
The number on a blood sugar test might look the same in both types of stage 2, but the underlying disease is completely different. In autoimmune stage 2 (type 1 path), the immune system is actively destroying the cells that make insulin, and progression to insulin dependence is nearly inevitable without intervention. In metabolic stage 2 (type 2 path), insulin resistance is the primary driver, and the disease course is more modifiable through behavior and, when needed, medication.
If you or a family member has been told you’re in “stage 2,” the most important thing to clarify is which staging system your doctor is using. Autoantibody testing is what separates the two. A positive result for two or more islet autoantibodies points toward the type 1 pathway, while their absence, combined with risk factors like excess weight and family history of type 2, points toward the metabolic pathway. The monitoring schedule, treatment options, and long-term outlook differ substantially depending on the answer.